Literature DB >> 1876774

Using empirical Bayes methods in biopharmaceutical research.

T A Louis1.   

Abstract

A compound sampling model, where a unit-specific parameter is sampled from a prior distribution and then observed are generated by a sampling distribution depending on the parameter, underlies a wide variety of biopharmaceutical data. For example, in a multi-centre clinical trial the true treatment effect varies from centre to centre. Observed treatment effects deviate from these true effects through sampling variation. Knowledge of the prior distribution allows use of Bayesian analysis to compute the posterior distribution of clinic-specific treatment effects (frequently summarized by the posterior mean and variance). More commonly, with the prior not completely specified, observed data can be used to estimate the prior and use it to produce the posterior distribution: an empirical Bayes (or variance component) analysis. In the empirical Bayes model the estimated prior mean gives the typical treatment effect and the estimated prior standard deviation indicates the heterogeneity of treatment effects. In both the Bayes and empirical Bayes approaches, estimated clinic effects are shrunken towards a common value from estimates based on single clinics. This shrinkage produces more efficient estimates. In addition, the compound model helps structure approaches to ranking and selection, provides adjustments for multiplicity, allows estimation of the histogram of clinic-specific effects, and structures incorporation of external information. This paper outlines the empirical Bayes approach. Coverage will include development and comparison of approaches based on parametric priors (for example, a Gaussian prior with unknown mean and variance) and non-parametric priors, discussion of the importance of accounting for uncertainty in the estimated prior, comparison of the output and interpretation of fixed and random effects approaches to estimating population values, estimating histograms, and identification of key considerations in the use and interpretation of empirical Bayes methods.

Mesh:

Year:  1991        PMID: 1876774     DOI: 10.1002/sim.4780100604

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

Review 1.  Methods in health service research. An introduction to bayesian methods in health technology assessment.

Authors:  D J Spiegelhalter; J P Myles; D R Jones; K R Abrams
Journal:  BMJ       Date:  1999-08-21

Review 2.  Data and models determine treatment proposals--an illustration from meta-analysis.

Authors:  U Helfenstein
Journal:  Postgrad Med J       Date:  2002-03       Impact factor: 2.401

Review 3.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

4.  Comparing methods to estimate treatment effects on a continuous outcome in multicentre randomized controlled trials: a simulation study.

Authors:  Rong Chu; Lehana Thabane; Jinhui Ma; Anne Holbrook; Eleanor Pullenayegum; Philip James Devereaux
Journal:  BMC Med Res Methodol       Date:  2011-02-21       Impact factor: 4.615

Review 5.  Hierarchical regression for epidemiologic analyses of multiple exposures.

Authors:  S Greenland
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

6.  A re-evaluation of random-effects meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson; David J Spiegelhalter
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-01       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.